Sanofi Entered into a Multi-Target Research Collaboration with Atomwise for AI-Powered Drug Discovery
Shots:
- Atomwise to receive $20M up front to identify, synthesize, and advance lead compounds for ~5 targets & is eligible to receive ~$1B in research, development, and sales milestones along with royalties that emerge from the collaboration
- The collaboration enables Sanofi to use Atomwise’s AtomNet platform for computational discovery and research of ~5 drug targets
- Atomwise's exclusive library of 3+ trillion synthesizable chemicals may be quickly searched using AI by the AtomNet platform which integrates deep learning for structure-based drug creation & accelerating the discovery of new therapies
Ref: Businesswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
